These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32513909)

  • 1. Erratum: The p66shc-Mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
    Zhang J; Li Y; Wang B; Luo Y; Shi J; Zhao B
    Med Sci Monit; 2020 Jun; 26():e926160. PubMed ID: 32513909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
    Zhang J; Li Y; Wang B; Luo Y; Shi J; Zhao B
    Med Sci Monit; 2020 Mar; 26():e921887. PubMed ID: 32191680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.
    Tomita K; Teratani T; Suzuki T; Oshikawa T; Yokoyama H; Shimamura K; Nishiyama K; Mataki N; Irie R; Minamino T; Okada Y; Kurihara C; Ebinuma H; Saito H; Shimizu I; Yoshida Y; Hokari R; Sugiyama K; Hatsuse K; Yamamoto J; Kanai T; Miura S; Hibi T
    J Hepatol; 2012 Oct; 57(4):837-43. PubMed ID: 22641095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/- mice via p66shc/cytochrome C cascade.
    Zhang Y; Wang C; Lu J; Jin Y; Xu C; Meng Q; Liu Q; Dong D; Ma X; Liu K; Sun H
    Aging (Albany NY); 2020 Feb; 12(3):2049-2069. PubMed ID: 32023549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
    Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
    Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line.
    Zhou D; Li BH; Wang J; Ding YN; Dong Y; Chen YW; Fan JG
    PLoS One; 2016; 11(10):e0165224. PubMed ID: 27760195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.
    Semba S; Trapasso F; Fabbri M; McCorkell KA; Volinia S; Druck T; Iliopoulos D; Pekarsky Y; Ishii H; Garrison PN; Barnes LD; Croce CM; Huebner K
    Oncogene; 2020 Mar; 39(10):2224-2226. PubMed ID: 31819168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-17 family-mediated regulation of Pknox1 influences hepatic steatosis and insulin signaling.
    Ye D; Lou G; Zhang T; Dong F; Liu Y
    J Cell Mol Med; 2018 Dec; 22(12):6167-6175. PubMed ID: 30338914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
    Fujiwara J; Sowa Y; Horinaka M; Koyama M; Wakada M; Miki T; Sakai T
    Int J Oncol; 2016 Feb; 48(2):854. PubMed ID: 26648205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carnosic acid attenuates acute ethanol-induced liver injury via a SIRT1/p66Shc-mediated mitochondrial pathway.
    Tian X; Hu Y; Li M; Xia K; Yin J; Chen J; Liu Z
    Can J Physiol Pharmacol; 2016 Apr; 94(4):416-25. PubMed ID: 26845416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retracted: Resveratrol inhibits oesophageal adenocarcinoma cell proliferation via AMP-activated protein kinase signaling.
    Asian Pac J Cancer Prev; 2017 Nov; 18(10):2895-2895. PubMed ID: 29171745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS; Diehl AM
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum.
    Expert Rev Hematol; 2015 Oct; 8(5):699. PubMed ID: 26343894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 attenuates oxidative stress-induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53-progerin interaction.
    Luo X; Jiang X; Li J; Bai Y; Li Z; Wei P; Sun S; Liang Y; Han S; Li X; Zhang B
    Cell Death Dis; 2019 Jun; 10(6):451. PubMed ID: 31171766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of farnesoid X receptor on lipid metabolism in L02 cells].
    Hong JL; Shen W; Bai MJ
    Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):935-9. PubMed ID: 19105941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment and optimization of hepatocyte steatosis model].
    Gao JX; Li XJ; Zhang W; Li YS; Tang HB
    Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):922-926. PubMed ID: 30669785
    [No Abstract]   [Full Text] [Related]  

  • 18. The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells.
    Perrini S; Tortosa F; Natalicchio A; Pacelli C; Cignarelli A; Palmieri VO; Caccioppoli C; De Stefano F; Porro S; Leonardini A; Ficarella R; De Fazio M; Cocco T; Puglisi F; Laviola L; Palasciano G; Giorgino F
    Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(10):G826-40. PubMed ID: 26336926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein.
    Wu YL; Peng XE; Zhu YB; Yan XL; Chen WN; Lin X
    J Virol; 2016 Feb; 90(4):1729-40. PubMed ID: 26637457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease.
    Kajor M; Kukla M; Waluga M; Liszka Ł; Dyaczyński M; Kowalski G; Żądło D; Berdowska A; Chapuła M; Kostrząb-Zdebel A; Bułdak RJ; Sawczyn T; Hartleb M
    Pol J Pathol; 2017; 68(2):117-127. PubMed ID: 29025245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.